Investing in mutual funds for retirement is never too late. And the Zacks Mutual Fund Rank can be an excellent tool for investors looking to invest in the best funds.
The best way to shortlist great mutual funds is to ensure solid performance, diversification, and low fees. Some are better than others, but utilizing the Zacks Mutual Fund Rank, we have identified three mutual funds that could be solid additions to one's retirement portfolio.
Let's break down some of the mutual funds with the top Zacks Mutual Fund Rank and the lowest fees.
Amana Growth Investor (AMAGX): 0.92% expense ratio and 0.62% management fee. AMAGX is a Large Cap Growth option; these mutual funds purchase stakes in numerous large U.S. companies that are expected to develop and grow at a faster rate than other large-cap stocks. AMAGX has achieved five-year annual returns of an astounding 15.09%.
Janus Henderson Global Life Science D (JNGLX) is a stand out amongst its peers. JNGLX is a Sector - Health mutual fund, which give investors an opportunity to focus on healthcare, one of the largest sectors of the American economy. With five-year annualized performance of 10.39%, expense ratio of 0.8% and management fee of 0.64%, this diversified fund is an attractive buy with a strong history of performance.
Oberweis Small-Cap Opportunities (OBSOX): 1.25% expense ratio and 0.8% management fee. OBSOX is a Small Cap Growth mutual fund and tends to feature small companies in up-and-coming industries and markets. The fund is mainly invested in equities, has a long reputation of salutary performance, and has yearly returns of 13.49% over the last five years.
There you have it. If your financial advisor had you put your money into any of our top-ranked funds, then they've got you covered. If not, you may need to talk.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Get Your Free (AMAGX): Fund Analysis Report
Get Your Free (JNGLX): Fund Analysis Report
Get Your Free (OBSOX): Fund Analysis Report